Back to my company list

Pheiron

The AI engine Fit Assessment

Beta

Pheiron leverages machine learning to discover patterns and develop targeted therapeutics, while also focusing on biomarker identification for personalized medicine.

Blurb

Pheiron offers a data-driven platform for health management, enhancing drug development with AI and causal insights.

HQ Location

Berlin (Germany)

Founded

2023

Employees

1 - 10

Total funding raised

Not available

Last Funding Event

Not available

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification

Pheiron provides a scalable, secure, and interoperable platform for deep data-driven health management. The company focuses on improving the probability of success in drug development by leveraging causal insights on targets and populations. Pheiron uses AI to map multimodal data to diseases, aiming to enhance the understanding of diseases and inform decision-making in drug development. The platform also supports large-scale exome sequence analysis to identify sex- and age-specific factors in health management.